Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone. Ozempic for blood sugar control and Wegovy for weight loss both use different ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

With up to 800 obese patients in Kent now eligible for Mounjaro on the NHS, those already using the weight loss jabs share their incredible stories.

Around a fifth of users report not losing the expected amounts of weight on Mounjaro, and doctors have some answers ...

Insulin changed the way we treat and manage diabetes. Chemotherapy has precipitously reduced the mortality rate of certain ...

The quest for weight loss has taken a dramatic turn. A wave of new-age solutions, from once-weekly injectables like Wegovy ...

WEIGHT loss jabs may also help ward off dementia, a new study suggests. Researchers found that semaglutide – the active ...

WITH Mounjaro users shedding nearly double the amount of weight compared to its other counterparts, it’s no wonder the ...

Although the study involved data from US patients, experts say its findings are relevant to countries like India where ...

Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...